| 前收市價 | 無 |
| 開市 | 無 |
| 買盤 | 無 |
| 賣出價 | 無 |
| 拍板 | 無 |
| 到期日 | 無 |
| 今日波幅 | 無 - 無 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
- infocast
諾和諾德中止腎病藥試驗 計提64億港元減值
丹麥藥廠諾和諾德(Novo Nordisk)表示,中止一項實驗性治療心臟病和嚴重腎臟病藥物(CDK)的後期研究,因此須計提約57億丹麥克朗(約64億港元)的減值損失。諾和諾德去年同意向 KBP BioSciences 支付高達13億丹麥克朗的代價,收購對方研發中用於治療心臟病和慢性腎臟病的藥物。獨立監測委員會最新得出結論認為,經過長達12周試驗性治療後,參與實驗的600多名患者仍未達致改善血壓的主要目標,諾和諾德決定中途放棄相關藥物的研發計劃。 (BC)#Novo Nordisk #諾和諾德
BenzingaNovo Nordisk Halts Late-Stage Study Of Experimental Hypertension Drug, Takes Over $800M Impairment Charge
On Wednesday, Novo Nordisk A/S (NYSE:NVO) announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint. CLARION-CKD was a multicenter, double-blind, placebo-controlled, randomized phase 3 study of ocedurenone for uncontrolled hypertension in patients with advanced chronic kidney disease (CKD). Also Read: Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression. CLARION-CKD follows the same inclusion criteria as the phase 2b BLOCK-CKD study, whi
Investor's Business DailyDow Jones Futures Fall; Tesla Rival Rivian Skyrockets, Nvidia Gets Price Target Hike
Futures were mixed Wednesday, but Tesla rival Rivian vaulted higher on a big investment. FedEx jumped after earnings. Nvidia extended Monday's bounce.
